| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Outlook Therapeutics Inc (NASDAQ: OTLK)
OTLK Technical Analysis
4
| As on 9th Jun 2023 OTLK STOCK Price closed @ 1.73 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.35 & Strong Buy for SHORT-TERM with Stoploss of 1.42 we also expect STOCK to react on Following IMPORTANT LEVELS. |
OTLKSTOCK Price
| Open | 1.78 | Change | Price | % |
| High | 1.78 | 1 Day | -0.01 | -0.57 |
| Low | 1.68 | 1 Week | 0.25 | 16.89 |
| Close | 1.73 | 1 Month | 0.64 | 58.72 |
| Volume | 944151 | 1 Year | 0.28 | 19.31 |
| 52 Week High 2.03 | 52 Week Low 0.87 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| OTLK Daily Charts |
OTLK Intraday Charts |
Whats New @ Bazaartrend |
OTLK Free Analysis |
|
|
OTLK Important Levels Intraday
| RESISTANCE | 1.92 |
| RESISTANCE | 1.86 |
| RESISTANCE | 1.82 |
| RESISTANCE | 1.78 |
| SUPPORT | 1.68 |
| SUPPORT | 1.64 |
| SUPPORT | 1.60 |
| SUPPORT | 1.54 |
OTLK Forecast May 2024
| 4th UP Forecast | 2.39 |
| 3rd UP Forecast | 2.18 |
| 2nd UP Forecast | 2.05 |
| 1st UP Forecast | 1.92 |
| 1st DOWN Forecast | 1.54 |
| 2nd DOWN Forecast | 1.41 |
| 3rd DOWN Forecast | 1.28 |
| 4th DOWN Forecast | 1.07 |
OTLK Weekly Forecast
| 4th UP Forecast | 2.00 |
| 3rd UP Forecast | 1.91 |
| 2nd UP Forecast | 1.86 |
| 1st UP Forecast | 1.81 |
| 1st DOWN Forecast | 1.65 |
| 2nd DOWN Forecast | 1.60 |
| 3rd DOWN Forecast | 1.55 |
| 4th DOWN Forecast | 1.46 |
OTLK Forecast2024
| 4th UP Forecast | 4.5 |
| 3rd UP Forecast | 3.61 |
| 2nd UP Forecast | 3.06 |
| 1st UP Forecast | 2.51 |
| 1st DOWN Forecast | 0.95 |
| 2nd DOWN Forecast | 0.4 |
| 3rd DOWN Forecast | -0.15 |
| 4th DOWN Forecast | -1.04 |
Outlook Therapeutics Inc ( NASDAQ USA Symbol : OTLK )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
OTLK Business Profile
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Address: Building F, Iselin, NJ, United States, 08830
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service